Publications by authors named "E R Rosenbaum"
Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.
View Article and Find Full Text PDFArticle Synopsis
- - Patients with advanced/metastatic urothelial carcinoma who previously responded to or maintained stable disease with pembrolizumab immunotherapy may benefit from retreatment after disease progression, based on a post hoc analysis involving 49 patients from earlier clinical trials.
- - The study found that 41% of these patients achieved an objective response following retreatment, with a notable percentage having had a complete response during the initial treatment, and the median duration of the response was around 14 months.
- - Additionally, the retreatment led to manageable adverse effects, with only 45% experiencing treatment-related events, indicating that pembrolizumab retreatment is a viable and relatively safe option for select patients.
We describe a unique case of sclerouveitis that progressed to endogenous endophthalmitis in a 69-year-old male with chronic lymphocytic leukemia (CLL). We highlight the risk of treating sclerouveitis with oral corticosteroids, which can exacerbate an infection and contribute to disease progression. A 69-year-old male with CLL on zanubrutinib, a second-generation Bruton's tyrosine kinase inhibitor, was admitted to the hospital for osteomyelitis of the left foot.
View Article and Find Full Text PDFThe aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS, SEF, or H-LGFMS/SEF, surgically treated with curative intent from January 2000 to September 2022, were enrolled from 14 countries and 27 institutions. Pathologic inclusion criteria were predefined by expert pathologists.
View Article and Find Full Text PDF